Protagonist Therapeutics, Inc.
PTGX
$86.65
$2.002.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.14% | -198.34% | -108.85% | 496.49% | -8.47% |
| Total Depreciation and Amortization | -46.44% | 7.92% | 50.75% | -17.16% | -27.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.38% | -21.88% | 81.87% | -13.57% | 0.62% |
| Change in Net Operating Assets | 823.41% | -103.11% | 174.34% | -6,284.51% | -100.90% |
| Cash from Operations | 93.27% | -122.96% | 529.65% | -4.72% | -110.37% |
| Capital Expenditure | 89.18% | -49.17% | -75.81% | 60.00% | -2,667.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -205.11% | 159.26% | -1,015.35% | 95.95% | -136.05% |
| Cash from Investing | -206.83% | 158.06% | -981.97% | 95.82% | -136.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 93.47% | -75.47% | 195.76% | -66.55% | 368.55% |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 93.47% | -74.44% | 183.87% | -66.55% | 368.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -289.37% | -31.72% | 225.19% | 84.91% | -222.64% |